TARS logo

Tarsus Pharmaceuticals, Inc. (TARS) EBIT

Annual EBIT:

-$108.11M+$24.56M(+18.51%)
December 31, 2024

Summary

  • As of today, TARS annual earnings before interest & taxes is -$108.11 million, with the most recent change of +$24.56 million (+18.51%) on December 31, 2024.
  • During the last 3 years, TARS annual EBIT has fallen by -$94.33 million (-684.98%).
  • TARS annual EBIT is now -7907.93% below its all-time high of -$1.35 million, reached on December 31, 2018.

Performance

TARS EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

Quarterly EBIT:

-$18.25M+$4.80M(+20.83%)
June 30, 2025

Summary

  • As of today, TARS quarterly earnings before interest & taxes is -$18.25 million, with the most recent change of +$4.80 million (+20.83%) on June 30, 2025.
  • Over the past year, TARS quarterly EBIT has increased by +$13.04 million (+41.67%).
  • TARS quarterly EBIT is now -270.30% below its all-time high of $10.71 million, reached on March 31, 2021.

Performance

TARS Quarterly EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

TTM EBIT:

-$83.33M+$13.04M(+13.53%)
June 30, 2025

Summary

  • As of today, TARS TTM earnings before interest & taxes is -$83.33 million, with the most recent change of +$13.04 million (+13.53%) on June 30, 2025.
  • Over the past year, TARS TTM EBIT has increased by +$62.00 million (+42.66%).
  • TARS TTM EBIT is now -13065.09% below its all-time high of -$633.00 thousand, reached on September 30, 2019.

Performance

TARS TTM EBIT Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTARSincome statement metrics

EBIT Formula

EBIT = Revenue − COGS − Operating Expenses

TARS EBIT Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+18.5%+41.7%+42.7%
3Y3 Years-685.0%-250.9%-48.9%
5Y5 Years-2415.3%-459.2%-401.8%

TARS EBIT Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-685.0%+18.5%-41.0%+55.4%-38.9%+42.7%
5Y5-Year-2415.3%+18.5%-270.3%+55.4%-2200.8%+42.7%
All-TimeAll-Time-7907.9%+18.5%-270.3%+55.4%>-9999.0%+42.7%

TARS EBIT History

DateAnnualQuarterlyTTM
Jun 2025
-
-$18.25M(+20.8%)
-$83.33M(+13.5%)
Mar 2025
-
-$23.05M(-10.1%)
-$96.37M(+10.9%)
Dec 2024
-$108.11M(+18.5%)
-$20.94M(+0.8%)
-$108.11M(+15.6%)
Sep 2024
-
-$21.10M(+32.5%)
-$128.11M(+11.8%)
Jun 2024
-
-$31.28M(+10.1%)
-$145.33M(-0.4%)
Mar 2024
-
-$34.78M(+15.0%)
-$144.69M(-9.1%)
Dec 2023
-$132.67M(-121.0%)
-$40.94M(-6.8%)
-$132.67M(-26.8%)
Sep 2023
-
-$38.32M(-25.1%)
-$104.66M(-18.6%)
Jun 2023
-
-$30.64M(-34.6%)
-$88.27M(-40.5%)
Mar 2023
-
-$22.76M(-76.0%)
-$62.83M(-4.7%)
Dec 2022
-$60.03M
-$12.94M(+41.0%)
-$59.99M(+3.0%)
Sep 2022
-
-$21.93M(-321.8%)
-$61.85M(-10.5%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$5.20M(+73.9%)
-$55.95M(-28.7%)
Mar 2022
-
-$19.92M(-34.6%)
-$43.47M(-238.6%)
Dec 2021
-$13.77M(+49.0%)
-$14.80M(+7.7%)
-$12.84M(-34.9%)
Sep 2021
-
-$16.04M(-320.2%)
-$9.52M(-162.8%)
Jun 2021
-
$7.28M(-32.0%)
-$3.62M(+74.4%)
Mar 2021
-
$10.71M(+193.4%)
-$14.17M(+47.5%)
Dec 2020
-$27.00M(-528.2%)
-$11.48M(-13.2%)
-$27.00M(-62.6%)
Sep 2020
-
-$10.14M(-210.8%)
-$16.61M(-134.0%)
Jun 2020
-
-$3.26M(-54.1%)
-$7.10M(-85.1%)
Mar 2020
-
-$2.12M(-95.4%)
-$3.83M(-123.4%)
Dec 2019
-$4.30M(-218.4%)
-$1.08M(-71.2%)
-$1.72M(-171.2%)
Sep 2019
-
-$633.00K
-$633.00K
Dec 2018
-$1.35M
-
-

FAQ

  • What is Tarsus Pharmaceuticals, Inc. annual earnings before interest & taxes?
  • What is the all-time high annual EBIT for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. annual EBIT year-on-year change?
  • What is Tarsus Pharmaceuticals, Inc. quarterly earnings before interest & taxes?
  • What is the all-time high quarterly EBIT for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. quarterly EBIT year-on-year change?
  • What is Tarsus Pharmaceuticals, Inc. TTM earnings before interest & taxes?
  • What is the all-time high TTM EBIT for Tarsus Pharmaceuticals, Inc.?
  • What is Tarsus Pharmaceuticals, Inc. TTM EBIT year-on-year change?

What is Tarsus Pharmaceuticals, Inc. annual earnings before interest & taxes?

The current annual EBIT of TARS is -$108.11M

What is the all-time high annual EBIT for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high annual earnings before interest & taxes is -$1.35M

What is Tarsus Pharmaceuticals, Inc. annual EBIT year-on-year change?

Over the past year, TARS annual earnings before interest & taxes has changed by +$24.56M (+18.51%)

What is Tarsus Pharmaceuticals, Inc. quarterly earnings before interest & taxes?

The current quarterly EBIT of TARS is -$18.25M

What is the all-time high quarterly EBIT for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high quarterly earnings before interest & taxes is $10.71M

What is Tarsus Pharmaceuticals, Inc. quarterly EBIT year-on-year change?

Over the past year, TARS quarterly earnings before interest & taxes has changed by +$13.04M (+41.67%)

What is Tarsus Pharmaceuticals, Inc. TTM earnings before interest & taxes?

The current TTM EBIT of TARS is -$83.33M

What is the all-time high TTM EBIT for Tarsus Pharmaceuticals, Inc.?

Tarsus Pharmaceuticals, Inc. all-time high TTM earnings before interest & taxes is -$633.00K

What is Tarsus Pharmaceuticals, Inc. TTM EBIT year-on-year change?

Over the past year, TARS TTM earnings before interest & taxes has changed by +$62.00M (+42.66%)
On this page